Patents by Inventor Jiann-Shiun Lai
Jiann-Shiun Lai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180339061Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.Type: ApplicationFiled: June 1, 2018Publication date: November 29, 2018Inventors: Cheng-Der Tony YU, Jiann-Shiun LAI, I-Ju CHEN, Chiu-Chun LIN
-
Patent number: 10138300Abstract: The present invention relates to an antibody or antigen-binding fragment thereof that bind human vascular endothelial growth factor receptor 2 (VEGFR-2). The present invention also relates to a method for inhibiting VEGFR-2-mediated signaling in a subject in need, a method for treating diseases and/or disorders caused by or related to VEGFR-2 activity and/or signaling in a subject afflicted with the diseases and disorders, a method for treating tumor in a subject afflicted with the tumor, a method for inhibiting cell proliferation of endothelial cells in a subject in need, and a method for detecting human vascular endothelial growth factor receptor in a sample.Type: GrantFiled: July 3, 2017Date of Patent: November 27, 2018Assignee: DEVELOPMENT CENTER FOR BIOTECHNOLOGYInventors: Jiann-Shiun Lai, Li-Shuang Ai, Yan-Da Lai, Yen-Yu Wu, Yi-San Tsai, Yi-Jiue Tsai, Juo-Yu Huang, Cheng-Chou Yu, Chuan-Lung Hsu, Chien-Tsun Kuan, Szu-Liang Lai, Li-Ya Wang
-
Publication number: 20180193481Abstract: Antibody drug conjugates (ADC's) comprising a drug conjugated to antibody or antigen binding fragments thereof that bind to Globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testicle cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.Type: ApplicationFiled: November 21, 2017Publication date: July 12, 2018Inventors: Michael Nientse Chang, Jiann-Shiun Lai, Wan-Fen Li, I-Ju Chen, Yi-Chien Tsai, Kai-Chuan Chen
-
Publication number: 20180186884Abstract: The present invention relates to an antibody or antigen-binding fragment thereof that bind human vascular endothelial growth factor receptor 2 (VEGFR-2). The present invention also relates to a method for inhibiting VEGFR-2-mediated signaling in a subject in need, a method for treating diseases and/or disorders caused by or related to VEGFR-2 activity and/or signaling in a subject afflicted with the diseases and disorders, a method for treating tumor in a subject afflicted with the tumor, a method for inhibiting cell proliferation of endothelial cells in a subject in need, and a method for detecting human vascular endothelial growth factor receptor in a sample.Type: ApplicationFiled: July 3, 2017Publication date: July 5, 2018Inventors: JIANN-SHIUN LAI, Li-Shuang Ai, Yan-Da Lai, Yen-Yu Wu, Yi-San Tsai, Yi-Jiue Tsai, Juo-Yu Huang, Cheng-Chou Yu, Chuan-Lung Hsu, Chien-Tsun Kuan, Szu-Liang Lai, Li-Ya Wang
-
Publication number: 20180134799Abstract: The present invention provides antibodies or the antigen-binding portion thereof, that bind to one or more carbohydrate antigens. Also disclosed herein are pharmaceutical pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.Type: ApplicationFiled: November 28, 2017Publication date: May 17, 2018Inventors: Cheng-Der Tony YU, Jiann-Shiun Lai, I-Ju Chen, Cheng-Chi Wang, Yi-Chien Tsai
-
Patent number: 9902779Abstract: The present invention provides antibodies or the antigen-binding portion thereof, that bind to one or more carbohydrate antigens. Also disclosed herein are pharmaceutical pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.Type: GrantFiled: April 10, 2015Date of Patent: February 27, 2018Assignee: OBI PHARMA INC.Inventors: Cheng-Der Tony Yu, Jiann-Shiun Lai, I-Ju Chen, Cheng-Chi Wang, Yi-Chien Tsai
-
Publication number: 20170283488Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.Type: ApplicationFiled: March 29, 2017Publication date: October 5, 2017Inventors: Cheng-Der Tony YU, Jiann-Shiun LAI, I-Ju CHEN, Chiu-Chun LIN
-
Publication number: 20170233480Abstract: The present invention relates to an antibody or antigen-binding fragment thereof that bind human vascular endothelial growth factor receptor 2 (VEGFR-2). The present invention also relates to a method for inhibiting VEGFR-2-mediated signaling in a subject in need, a method for treating diseases and/or disorders caused by or related to VEGFR-2 activity and/or signaling in a subject afflicted with the diseases and disorders, a method for treating tumor in a subject afflicted with the tumor, a method for inhibiting cell proliferation of endothelial cells in a subject in need, and a method for detecting human vascular endothelial growth factor receptor in a sample.Type: ApplicationFiled: December 29, 2016Publication date: August 17, 2017Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGYInventors: JIANN-SHIUN LAI, LI-SHUANG AI, YAN-DA LAI, YEN-YU WU, YI-SAN TSAI, YI-JIUE TSAI, JUO-YU HUANG, CHENG-CHOU YU, CHUAN-LUNG HSU, CHIEN-TSUN KUAN, SZU-LIANG LAI, LI-YA WANG
-
Publication number: 20170101462Abstract: The present invention provides antibodies or the antigen-binding portion thereof to a tumor-associate carbohydrate antigen. Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.Type: ApplicationFiled: October 7, 2016Publication date: April 13, 2017Inventors: Cheng-Der Tony YU, Jiann-Shiun Lai, I-Ju Chen
-
Patent number: 9527922Abstract: A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENO1 (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO: 6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO: 7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO: 3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO: 4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.Type: GrantFiled: December 31, 2014Date of Patent: December 27, 2016Assignees: Development Center for Biotechnology, DCB-USA LLC, National Health Research InstitutesInventors: Shih-Chong Tsai, Ta-Tung Yuan, Shih-Chi Tseng, Jiann-Shiun Lai, Chia-Cheng Wu, Chao-Yang Huang, Ya-Wei Tsai, Ying-Yung Lok, Chung-Hsiun Wu, Neng-Yao Shih, Ko-Jiunn Liu, Li-Tzong Chen
-
Patent number: 9428575Abstract: An anti-granulysin antibody, or an scFv or Fab fragment thereof, capable of binding to an epitope region from R64 to R113 of granulysin and capable of neutralizing an activity of granulysin. The antibody may contain a sequence selected from the sequences of SEQ ID NO:82 to SEQ ID NO:195, or the antibody may contain a sequence selected from the sequences of SEQ ID NO:39 to SEQ ID NO:76. The antibody may be a monoclonal antibody. A method for treating or preventing an unwanted immune response disorder includes administering to a subject in need thereof an effective amount of an anti-granulysin antibody capable of neutralizing the activity of granulysin. The unwanted immune response disorder may be SJS, TEN, or GVHD.Type: GrantFiled: December 31, 2013Date of Patent: August 30, 2016Assignees: Development Center for Biotechnology, DCB-USA LLC, Academia SinicaInventors: Jiann-Shiun Lai, Hung-Ling Wang, Chao-Yang Huang, Ying-Yung Lok, Yuan-Tsong Chen, Woan-Eng Chan, Chih-Yung Hu
-
Publication number: 20160185876Abstract: A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENO1 (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO: 6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO: 7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO: 3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO: 4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.Type: ApplicationFiled: December 31, 2014Publication date: June 30, 2016Applicants: Development Center for Biotechnology, DCB-USA LLC, National Health Research InstitutesInventors: Shih-Chong Tsai, Ta-Tung Yuan, Shih-Chi Tseng, Jiann-Shiun Lai, Chia-Cheng Wu, Chao-Yang Huang, Ya-Wei Tsai, Ying-Yung Lok, Chung-Hsiun Wu, Neng-Yao Shih, Ko-Jiunn Liu, Li-Tzong Chen
-
Publication number: 20160130336Abstract: An anti-VEGF antibody, or a binding fragment thereof, includes a heavy-chain variable region that comprises: (1) a CDRH1 sequence selected from SEQ ID NO: 17, 20, 23, 26, 29, 32, 35, or 38), (2) a CDRH2 sequence selected from SEQ ID NO:18, 21, 24, 27, 30, 33, 36, or 39, and (3) a CDRH3 sequence selected from SEQ ID NO:19, 22, 25, 28, 31, 34, 37, or 40; and a light-chain variable region that comprises: (1) a CDRL1 sequence selected from SEQ ID NO: 41, 44, 47, 50, 53, 56, 59, or 62, (2) a CDRL2 sequence selected from SEQ ID NO: 42, 45, 48, 51, 54, 57, 60, or 63, and (3) a CDRL3 sequence selected from SEQ ID NO: 43, 46, 49, 52, 55, 58, 61, or 64. A method for treating or preventing a VEGF-related disorder, e.g., diabetic retinopathy, age-related macular degeneration, or cancer, uses the antibodies.Type: ApplicationFiled: December 29, 2014Publication date: May 12, 2016Applicants: Development Center for Biotechnology, DCB-USA LLCInventors: Jiann-Shiun Lai, Yan-Da Lai, Yen-Yu Wu, Yi-Jiue Tsai, Yu-Ying Lin
-
Publication number: 20160068595Abstract: A humanized antibody, or a scFv, Fab, or F(ab?)2 thereof, includes: a heavy chain variable region, or a homologous variant thereof, wherein the heavy chain variable region includes: heavy chain framework regions, CDRH1 that has the sequence of SEQ ID NO:19, CDRH2 that has the sequence of SEQ ID NO:20, and CDRH3 that has the sequence of SEQ ID NO:21, wherein the heavy chain variable region and the homologous variant share at least 90% sequence identity in the heavy chain framework regions; and a light chain variable region, or a homologous variant thereof, that includes: light chain framework regions, CDRL1 that has the sequence of SEQ ID NO:22, CDRL2 that has the sequences of SEQ ID NO:23, and CDRL3 that has the sequences of SEQ ID NO:24, wherein the light chain variable region and the homologous variant share at least 90% sequence identity in the light chain framework regions.Type: ApplicationFiled: April 18, 2014Publication date: March 10, 2016Applicants: Development Center for Biotechnology, DCB-USA LLCInventors: Chia-Cheng Wu, Chao-Yang Huang, Yu-Ying Lin, Yu-Jung Chen, Jiann-Shiun Lai
-
Publication number: 20140314741Abstract: FLB5M5 is a humanized monoclonal antibody with three mutated amino acids in the CDRs relative to its parental mouse anti-IL-20 monoclonal antibody 7E and five mutated amino acids of the light-chain framework region relative to the amino acids of the light-chain framework region of human V?2. FLB5M5 not only retains binding specificity toward IL-20 but also has a better binding affinity than 7E for IL-20. FLB5M5 is also less immunogenic than 7E to the human host in clinical application. A mutation in the light chain CDR to tyrosine increases binding affinity to IL-20. A method for treating rheumatoid arthritis using FLB5M5 is also disclosed.Type: ApplicationFiled: April 18, 2013Publication date: October 23, 2014Applicant: DEVELOPMEN CENTER FOR BIOTECHNOLOGYInventors: CHIA-CHENG WU, CHAO-YANG HUANG, YU-YING LIN, YU-JUNG CHEN, JIANN-SHIUN LAI
-
Publication number: 20140186352Abstract: An anti-granulysin antibody, or an scFv or Fab fragment thereof, capable of binding to an epitope region from R64 to R113 of granulysin and capable of neutralizing an activity of granulysin. The antibody may contain a sequence selected from the sequences of SEQ ID NO:82 to SEQ ID NO:195, or the antibody may contain a sequence selected from the sequences of SEQ ID NO:39 to SEQ ID NO:76. The antibody may be a monoclonal antibody. A method for treating or preventing an unwanted immune response disorder includes administering to a subject in need thereof an effective amount of an anti-granulysin antibody capable of neutralizing the activity of granulysin. The unwanted immune response disorder may be SJS, TEN, or GVHD.Type: ApplicationFiled: December 31, 2013Publication date: July 3, 2014Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGYInventors: Jiann-Shiun Lai, Hung-Ling Wang, Chao-Yang Huang, Ying-Yung Lok
-
Patent number: 8431118Abstract: The invention provides antibodies and polypeptides that specifically bind to the glycoprotein D of herpes simplex virus (HSV) and use of the antibodies and polypeptides for treating or diagnosing HSV infections.Type: GrantFiled: July 11, 2012Date of Patent: April 30, 2013Assignee: DCB-USA LLCInventors: Jiann-Shiun Lai, Woan-Eng Chan
-
Publication number: 20120282260Abstract: The invention provides antibodies and polypeptides that specifically bind to the glycoprotein D of herpes simplex virus (HSV) and use of the antibodies and polypeptides for treating or diagnosing HSV infections.Type: ApplicationFiled: July 11, 2012Publication date: November 8, 2012Applicant: DCB-USA LLCInventors: Jiann-Shiun LAI, Woan-Eng Chan
-
Patent number: 8252906Abstract: The invention provides antibodies and polypeptides that specifically bind to the glycoprotein D of herpes simplex virus (HSV) and use of the antibodies and polypeptides for treating or diagnosing HSV infections.Type: GrantFiled: December 31, 2009Date of Patent: August 28, 2012Assignee: DCB-USA LLCInventors: Jiann-Shiun Lai, Woan-Eng Chan
-
Patent number: 7763261Abstract: The present invention features a human antibody that specifically binds to human cytomegalovirus (HCMV), its encoding nucleic acid(s), and use of the antibody/nucleic acid(s) in treating HCMV infection.Type: GrantFiled: October 27, 2008Date of Patent: July 27, 2010Assignee: DCB-USA LLCInventors: Jiann-Shiun Lai, Chi-Kuan Chen, Young-Sun Lin, Chao-Yang Huang